Chronic myeloid leukemia patients who took 400 mg of nilotinib twice daily had a 97% overall survival rate after 3 years, based on data from 73 patients, explains Dr. Gianantonio Rosti. See the Internal Medicine News story at http://tinyurl.com/27nwkcb